Novozymes Sales Rise 7% in 2012

Novozymes’s 2012 sales rose 7% in local currency to more than $2.0 billion, the company reported. Net profit rose 10% during that time, to nearly $360 million. This year, the company expects organic sales growth of 5-8%.


“We delivered strong earnings growth and record profitability in a year when organic sales growth was challenged and came in at 4%—below our ambition,” says Steen Riisgaard, president and CEO. “With 2012 behind us, we have reviewed our long-term growth scenarios and decided to adjust our long-term financial targets. We are still confident that we can reach the long-term sales growth target of more than 10%, although not until 2015.”


Riisgaard predicted that profitability will remain at current levels, and the company is raising its target for EBIT margin to more than 24%. The ROIC target is confirmed as more than 22%. Riisgaard reiterated that the company’s strategy is unchanged and, under the leadership of the new President and CEO Peder Holk Nielsen, Novozymes will continue to focus on innovation, partnerships and sustainability.